| 시간 |
프로그램 |
연자 |
| 13:00-13:05 |
인사말 |
김난희 (당뇨병신증 연구회 회장) |
| 13:05-13:15 |
History of Research Group of Diabetic Kidney Disease in KDA |
최동섭 (고려의대) |
| Session1: Recent issues of Diabetic kidney disease |
좌장: 최동섭, 이은영 |
| 13:15-13:35 |
Paradigm shift in clinical practice, eGFR and/or albuminuria as indicator for DKD? |
김소헌 (인하의대) |
| 13:35-13:55 |
New ADA_ASN joint statement |
서미혜 (순천향의대) |
| 13:55-14:15 |
Choice of Renal Endpoint in DKD trials |
권순효 (순천향의대) |
| 14:15-14:35 |
패널토의 |
김동림 (건국의대), 정인하 (고려의대), 한상엽 (인제의대) |
| Session2: How to prevent Diabetic Kidney Disease |
좌장: 하헌주, 정춘희 |
| 14:35–14:55 |
The effect of Finerenone on diabetic kidney disease |
김경아 (동국의대) |
| 14:55-15:15 |
The effect of GLP-1 RA on diabetic kidney disease |
전재한 (경북의대) |
| 15:15-15:35 |
Possible Emerging Diabetic Drugs for Diabetic kidney disease |
문주영 (경희의대) |
| 15:35-15:55 |
패널토의 |
최원석 (전남의대), 송선옥 (국민건강보험일산병원), 김효정 (을지의대) |
| 15:55-16:20 |
Coffee Break |
| Session3: The effect of SGLT2 inhibitor on CardioRenal Metabolism |
좌장: 이대호, 김난희 |
| 16:20-16:40 |
Cardiologist view |
오재원 (연세의대) |
| 16:40-17:00 |
SGLT2 inhibitor: nephrologist perspective |
유태현 (연세의대) |
| 17:00-17:20 |
An endocrinologist view |
김남훈 (고려의대) |
| 17:20-17:40 |
패널토의 |
김수경 (경상의대), 차진주 (고려의대), 김태균 (포함세명기독병원) |
| 17:40-17:50 |
맺음말 |
